Combining Voltaren SR with other NSAIDs or high-dose aspirin increases the risk of gastrointestinal bleeding and should be avoided unless specifically directed by a prescriber. If additional analgesia is needed, acetaminophen (paracetamol) is generally considered safer, but you should discuss this with your healthcare provider.
NSAIDs, including diclofenac, can cause fluid retention and may raise blood pressure in susceptible individuals. Regular monitoring is advisable for patients with hypertension or those taking antihypertensive medication.
Take the missed tablet as soon as you remember, provided it is at least 12 hours before the next scheduled dose. Do not double the dose to catch up. Adjust the timing to maintain a roughly 24-hour interval thereafter.
Pilots should be aware that dizziness or visual disturbances from diclofenac could impair flight performance. Aviation medical regulations typically require reporting of any medication that may affect cognition or alertness; consult the relevant aviation authority.
Both are NSAIDs, but diclofenac (Voltaren SR) is often prescribed at a lower daily dose due to its potency. Clinical guidelines suggest individual response and tolerability guide the choice; no single drug is universally superior.
Intense exercise can increase the risk of dehydration and renal strain. Since NSAIDs may further affect kidney function, ensure adequate hydration and discuss continued use with a sports medicine professional.
The exact excipient list varies by manufacturer and region. Common inactive components may include microcrystalline cellulose, lactose, and magnesium stearate. If you have known excipient allergies, review the product label or ask your pharmacist.
While diclofenac can provide analgesia for dental pain, it is not the first-line recommendation for post-extraction discomfort in the UK. Dentists often prescribe paracetamol or a short course of ibuprofen; consult your dentist for specific advice.
Voltaren SR is a prescription-only medicine. In the UK, repeat prescriptions are usually arranged by the prescriber after a review of treatment efficacy and safety. Automated repeat dispensing is not permitted without a clinician’s approval.
Long-term NSAID therapy should be periodically reassessed. Guidelines suggest limiting continuous use to the lowest effective dose and conducting regular monitoring of renal, hepatic, and cardiovascular status. Individual duration depends on disease severity and risk factors.
Voltaren SR is a brand-name medication that contains diclofenac sodium as its active ingredient. It belongs to the pain-relief therapeutic class, specifically the non-steroidal anti-inflammatory drug (NSAID) group. Voltaren SR is supplied as a sustained-release (SR) pill in a 100 mg strength. In the United Kingdom it is classified as a prescription-only medicine (POM) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The formulation is designed to release diclofenac gradually over several hours, providing prolonged symptom control compared with immediate-release tablets.
Diclofenac sodium belongs to the NSAID family. Its primary mechanism is the inhibition of cyclooxygenase (COX) enzymes, particularly COX-2, which are responsible for converting arachidonic acid into prostaglandins. Prostaglandins mediate pain, inflammation, and fever. By reducing prostaglandin synthesis, diclofenac lowers the sensitivity of nerve endings to pain signals and diminishes inflammation in affected tissues.
The sustained-release matrix allows the drug to be absorbed more slowly, which can reduce gastrointestinal irritation compared with immediate-release NSAIDs, although the overall risk profile remains similar.
Voltaren SR is authorised by the MHRA for the following indications:
These indications are based on clinical trials that demonstrated the drug’s efficacy in reducing pain scores and improving mobility in adult patients. The medication is intended for adult use; it is not recommended for routine use in children or adolescents.
Some clinical reports have explored diclofenac’s utility beyond its approved indications, for example in the management of migraine attacks or post-operative pain. These uses are not approved by the MHRA and should only be considered under specialist supervision, weighing the potential benefits against known cardiovascular and gastrointestinal risks.
Disclaimer: Off-label use requires medical supervision and an individualized risk assessment.
These effects are generally transient and may be mitigated by taking the tablet with food.
Patients experiencing sudden abdominal pain, vomiting blood, black stools, chest pain, or severe skin rash should seek immediate medical attention.
If detailed interaction data for Voltaren SR are limited, patients should inform their healthcare provider of all medicines, supplements, and herbal products before starting therapy.
This article provides educational information about Voltaren SR and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
